Ultragenyx Pharmaceutical Inc. announced that Crysvita™ (Burosumab Injection) has been approved by Health Canada for the treatment of Tumour Induced Osteomalacia (TIO) in adults. Crysvita is also approved for the treatment of X-Linked Hypophosphatemia. TIO is a rare disease that is characterized by the development of tumours that cause weakened and softened bones. The tumours associated with TIO release a protein known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels. CRYSVITA (Burosumab Injection) is indicated for the treatment of fibroblast growth factor 23 (FGF23)–related hypophosphatemia in tumour-induced osteomalacia (TIO) associated with tumours that cannot be curatively resected or localized in adult patients. Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.